AbbVie today announced the start of its two-week public voting period for the 2023 Thriving Undergraduate and Graduate Scholarships. Following this voting period, scholarships totaling $25,000 each will be awarded to two…
At an Extraordinary General Meeting held today, Novartis shareholders approved the proposed 100% Spin-off of Sandoz, the Generics and Biosimilars business of Novartis. Shareholders also approved an ordinary capital decrease…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the European Commission (EC) has approved an expanded indication for ERVEBO for active immunization…
CVS Health® Corporation (NYSE: CVS) today announced additional responsibilities for several members of the company’s executive leadership team, effective immediately: “At a time when we are accelerating our strategy to deliver…
Sandoz today published a supplement to its Listing Prospectus of August 18, 2023, ahead of an Extraordinary General Meeting (EGM) of Novartis shareholders. Scheduled to take place on September 15,…
Optum, a diversified health services company, and Capella University, an accredited online university, announced a new educational program designed to address the growing need for skilled, advanced practice nurses. The…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced new, 10-year long-term follow-up (LTFU) data published in the peer reviewed journal, Pediatrics, for girls and boys who…
Following FDA approval, CVS Pharmacy® is now offering over-the-counter (OTC) naloxone, brand name NARCAN®, at more than 7,500 locations nationwide, making it easier and more discrete than ever to purchase the safe…
Following FDA approval, CVS Pharmacy® is now offering over-the-counter (OTC) naloxone, brand name NARCAN®, at more than 7,500 locations nationwide, making it easier and more discrete than ever to purchase the safe…
Cardinal Health (NYSE: CAH) announced today the launch of its next generation NTrainer™ System 2.0, a medical device designed to help premature and newborn infants develop the oral coordination skills…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the company’s Phase 3 clinical program, CORALreef, for MK-0616, an investigational, oral…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today provided an update on the Phase 3 LEAP-010 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy,…